Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
about
Diabetes and cancer: two diseases with obesity as a common risk factorThe New Era of Drug Therapy for Obesity: The Evidence and the ExpectationsObesity pharmacotherapy: current perspectives and future directionsGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesChronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetesGlucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillanceDiabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesSelecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatideSafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.Pharmacological treatment of obesity in patients with polycystic ovary syndrome.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitusGLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-contPharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Aqueous fraction of Beta vulgaris ameliorates hyperglycemia in diabetic mice due to enhanced glucose stimulated insulin secretion, mediated by acetylcholine and GLP-1, and elevated glucose uptake via increased membrane bound GLUT4 transporters.Ketoacidosis in type 2 diabetes--is it type 1 and 1/2 diabetes?Incretin therapy--present and future.GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Update on Safety Issues Related to Antihyperglycemic TherapyLiraglutide for treating type 1 diabetes.A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancerSequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targetsDeveloping therapies for the metabolic syndrome: challenges, opportunities, and… the unknown.Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.The cardiovascular effects of GLP-1 receptor agonists.Clinical comments related to medullary thyroid cancer diagnosis and management.Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatmentInterpreting adverse signals in diabetes drug development programs.Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerationsComparative effectiveness of liraglutide in the treatment of type 2 diabetes.
P2860
Q26822753-FDF0B37A-3C29-4DBF-BA04-8BC50C992822Q26827555-C2FEABAD-924C-4C30-8F5B-5A799D2957AEQ26828559-B8245FCB-659A-4112-84F9-4523DDE9014DQ28067465-84B40D93-E577-4671-BACD-6E4810D31D39Q28741419-407A81DB-B36C-4F45-9F26-A17ED358B8E0Q30513617-D2FBD705-A7E6-4863-91FB-66770EB12906Q33585560-3D02B75D-5B94-4108-AF30-C9631FDCE13BQ33605813-76BFBFD6-B462-4165-8F64-8D9729F3DCD6Q33786150-69925FF2-FF56-453A-903C-51BA5762A9BAQ33949418-879C8EB9-067A-4ECF-ACEA-E23F0359010EQ33949425-F773425F-2792-4521-AF71-5E73AF94D506Q34133324-DF6AF9E5-10D9-4BD9-B9AA-F09D279E64E1Q34135837-92599696-8C0B-44F5-BA90-BA08E0C5476CQ34237350-ED4C010A-2F2B-49B2-BEED-C67CFD5BB297Q34442683-924F709E-E31D-4443-958D-FD43E425FA16Q34496741-2FD2227D-65B3-4BC2-823D-EE3549ED4C03Q34511743-E522A38A-775A-471C-947E-353B50A995E9Q34620493-DD29F551-95D0-480B-A3EB-47DE24AE6648Q35022184-47EF0384-0967-4433-BF7F-E8D662A374BAQ35043882-78C0B098-381A-441A-A31E-575307704A78Q35171407-FB439045-4665-4B66-A50C-76D4B818CA36Q35760283-90F02D38-9BBE-47F0-8597-7AE979ABED50Q35762689-FDCAEEA2-7869-44FE-871D-B893BD2CD3E3Q35906506-402BB115-14AB-4647-A8A3-1EF556724A0DQ35910429-128B2DC5-F80F-45C6-A216-66132CFB2772Q35939660-998D2162-92DB-425C-9FA4-04877DE382E9Q36011482-1049E2E6-EB5B-4D72-80F5-08BAA305F9C4Q36047167-A9E56ECB-BD7B-408E-97AC-71EC284D45F5Q36329929-DC060E42-8BC2-4AF3-A940-FF9DB06A2616Q36355550-3A396EA2-F199-4B66-A7BB-2DA837D5F1F0Q36368998-E5E4A482-7B54-4E6D-AB41-FB77CF551E45Q36690566-6B3970EB-E969-4B17-9657-B5F6E8C1CA0DQ36783681-F6BA6E16-D646-46D8-BE92-6A64B28CE445Q36942108-274B1A6E-1C2D-4C5E-B0D1-40647DA6D989Q36942266-D40770AC-885D-4ED5-858B-095DF2BB17BFQ37102861-38F0C2AF-AE94-46A8-A0A9-EAD1A19147C9Q37410215-182A0FA9-688E-499E-8B52-BEF73A712E50Q37517909-0B99B381-567B-437E-AB1E-A310DBC6B830Q37577148-6DCC71B0-EB2F-4A5C-80D8-E2CDBE1EA868Q37659673-F6976DCC-20CE-4C67-B235-9E9635F5A20D
P2860
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@ast
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@en
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@nl
type
label
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@ast
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@en
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@nl
prefLabel
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@ast
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@en
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@nl
P356
P1476
Weighing risks and benefits of ...... of a new antidiabetic therapy.
@en
P2093
Curtis Rosebraugh
Mary Parks
P304
P356
10.1056/NEJMP1001578
P407
P577
2010-02-17T00:00:00Z